MedinCell: initiates Phase 3 study on antipsychotic drug
The aim is to evaluate the efficacy and safety of what could be the first subcutaneous formulation of long-acting olanzapine injection (LAI) for the treatment of schizophrenic patients.
The first patients are expected to be enrolled in the coming days.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction